secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0000105770-26-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q4 adj EPS $2.04, +12.1% YoY; guides FY2026 $7.85-$8.20
-------------------------------------------------------------------

- Q4 net sales $805M (+7.5% reported, +3.3% organic); HVP Components $389.8M (+20.3%, +15.1% organic).
- Full-year 2025: net sales $3.074B (+6.3%); diluted EPS $6.79 (+1.5%), adj-diluted EPS $7.29 (+8.0%).
- FY2026 guidance: net sales $3.215B-$3.275B (4.6%-6.5% growth); adj-diluted EPS $7.85-$8.20 (+7.7%-12.5%).
- Operating cash flow $754.8M (+15.5%); free cash flow $468.9M (+69.6%); repurchased 552,593 shares for $134M.
- Expects mid-2026 close of SmartDose 3.5mL sale to AbbVie; device generated $55M in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/0000105770-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/wst-20260212.htm
  HTML page:      https://secwatch.observer/filing/0000105770-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer